Better treatment outcomes with aripiprazole long-acting injection in community and incarcerated patients with serious mental illness
ImportanceAripiprazole, a partial D2 receptor agonist, is proposed to enhance prefrontal cortex (PFC) dopamine function, improving working memory and GABA transmission, which supports social functioning. Long-acting injectable (LAI) antipsychotics are known to improve patient adherence, leading to e...
Saved in:
| Main Authors: | Erasmia I. Koiliari, Ioannis Mouzas, Georgios Alevizopoulos, Otto Lesch, Henriette Walter, Emmanouil L. Pasparakis |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Psychiatry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2025.1499400/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The impact of aripiprazole on neurocognitive function in individuals at clinical high risk for psychosis: A comparison with olanzapine and non-antipsychotic treatment
by: JiaHui Zeng, et al.
Published: (2025-01-01) -
Aripiprazole use as a cause of dopamine agonist failure in the treatment of prolactinomas
by: Edward Mignone, et al.
Published: (2025-01-01) -
Otizm ve tourette sendromu birlikteliğinde düşük doz aripiprazol monoterapisinin etkinliği: olgu sunumu
by: Necati Uzun
Published: (2018-01-01) -
Comparative effectiveness of aripiprazole and olanzapine on neurocognitive profile of patients with schizophrenia
by: Sanya Sharma, et al.
Published: (2023-10-01) -
Agar/β-Cyclodextrin Composite Cryogels for Controlled Release of Aripiprazole
by: Siyka Stoilova, et al.
Published: (2025-02-01)